Rockefeller Capital Management
RLMD icon

Rockefeller Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Rockefeller Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-27
Closed – – 3502
2022
Q4 		$0 Hold
27
– – ﹤0.01% 4155
2022
Q3 		$1K Hold
27
– – ﹤0.01% 3774
2022
Q2 		$0 Hold
27
– – ﹤0.01% 4346
2022
Q1 		$0 Hold
27
– – ﹤0.01% 4035
2021
Q4 		$0 Hold
27
– – ﹤0.01% 3960
2021
Q3 		$0 Hold
27
– – ﹤0.01% 3818
2021
Q2 		$0 Hold
27
– – ﹤0.01% 3577
2021
Q1 		$0 Hold
27
– – ﹤0.01% 3369
2020
Q4 		$0 Hold
27
– – ﹤0.01% 2987
2020
Q3 		$1K Hold
27
– – ﹤0.01% 2524
2020
Q2 		$1K Buy
+27
New +$1.14K ﹤0.01% 2493

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rockefeller Capital Management's RLMD Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Relmada Therapeutics (RLMD) in Q1 2023, closing a stake of 27 shares.

Rockefeller Capital Management first reported a position in RLMD in Q2 2020 and held it in 11 quarters. The position peaked at $1K in Q3 2022. 91 funds tracked by Wall St. Rank hold RLMD as of Q1 2023.

  • Rockefeller Capital Management reported no remaining Relmada Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 27 Relmada Therapeutics shares in Q1 2023.
  • Rockefeller Capital Management first reported a position in Relmada Therapeutics in Q2 2020 and held it in 11 quarters.
  • Rockefeller Capital Management's Relmada Therapeutics position peaked at $1K in Q3 2022.
  • 91 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.